Nodality Enters into a Multi-Year Strategic Collaboration with Pfizer in Autoimmune Disease
09:00 EDT 9 Aug 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Nodality, Inc. today announced a strategic collaboration with Pfizer
Inc. for the use of Nodality’s proprietary Single Cell Network Profiling
(SCNP) technology as a tool for the development of Pfizer compounds. The
agreement e...
Other Sources for this Article
Nodality
Daniel Dornbusch, 650-827-8022
daniel.dornbusch@nodality.com
or
Media:
Burns
McClellan
Justin Jackson, 212-213-0006
jjackson@burnsmc.com
More From BioPortfolio on "Nodality Enters into a Multi-Year Strategic Collaboration with Pfizer in Autoimmune Disease"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
